Photo of Miles A. Miller,  PhD

Miles A. Miller, PhD

Massachusetts General Hospital

Massachusetts General Hospital


miles.miller@mgh.harvard.edu

Miles A. Miller, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Radiology, Harvard Medical School
  • Principal Investigator, Center for Systems Biology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our lab advances multiscale network biology by using computational and experimental methods to understand how mammalian cell signaling and regulation integrate across multiple scales, from the molecular to whole-body level. We combine multiplexed measurements with in vivo imaging and mathematical modeling to distill principles of cellular communication. We particularly focus on inflammation and cancer, where abnormal signals in multiple cell types promote disease progression and are therapeutically targeted. We have applied this approach to study the combined transport and action of both traditional drugs in the treatment of cancer, as well as therapies that use engineered materials such as nanoparticles to probe and exploit features of the tumor microenvironment.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Quintana JM, Jiang F, Kang M, Valladolid Onecha V, Könik A, Qin L, Rodriguez VE, Hu H, Borges N, Khurana I, Banla LI, Le Fur M, Caravan P, Schuemann J, Bertolet A, Weissleder R, Miller MA, Ng TSC. Localized In Vivo Prodrug Activation Using Radionuclides. J Nucl Med 2025; 66:91-97. PubMed
  • Song J, Cho MH, Cho H, Song Y, Lee SW, Nam HC, Yoon TH, Shin JC, Hong JS, Kim Y, Ekanayake E, Jeon J, You DG, Im SG, Choi GS, Park JS, Carter BC, Balaj L, Seo AN, Miller MA, Park SY, Kang T, Castro CM, Lee H. Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE. Nat Biotechnol 2024. PubMed
  • Quintana JM, Carlson JCT, Scott E, Ng TSC, Miller MA, Weissleder R. Scission-Enhanced Molecular Imaging (SEMI). Bioconjug Chem 2024. PubMed
  • Quintana JM, Kang M, Hu H, Ng TSC, Wojtkiewicz GR, Scott E, Parangi S, Schuemann J, Weissleder R, Miller MA. Extended Pharmacokinetics Improve Site-Specific Prodrug Activation Using Radiation. ACS Cent Sci 2024; 10:1371-1382. PubMed
  • Jeng-Miller KW, Miller MA, Heier JS. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation. Oncologist 2024; 29:e616-e621. PubMed
  • Kang M, Quintana J, Hu H, Teixeira VC, Olberg S, Banla LI, Rodriguez V, Hwang WL, Schuemann J, Parangi S, Weissleder R, Miller MA. Sustained and Localized Drug Depot Release Using Radiation-Activated Scintillating Nanoparticles. Adv. Mater. Weinheim 2024. PubMed
  • Hu H, Ng TSC, Kang M, Scott E, Li R, Quintana JM, Matvey D, Vantaku VR, Weissleder R, Parangi S, Miller MA. Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response. Clin Cancer Res 2023. PubMed
  • Dosta P, Puigmal N, Cryer AM, Rodríguez AL, Scott E, Weissleder R, Miller MA, Artzi N. Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers. Theranostics 2023; 13:1-15. PubMed
  • Lugani S, Halabi EA, Oh J, Kohler RH, Peterson HM, Breakefield XO, Chiocca EAA, Miller MA, Garris CS, Weissleder R. Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti-Tumor Immunity in Murine Glioblastoma. Adv. Mater. Weinheim 2022. PubMed
  • Quintana JM, Arboleda D, Hu H, Scott E, Luthria G, Pai S, Parangi S, Weissleder R, Miller MA. Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. Bioconjug Chem 2022; 33:1474-1484. PubMed
  • Ng TSC, Hu H, Kronister S, Lee C, Li R, Gerosa L, Stopka SA, Burgenske DM, Khurana I, Regan MS, Vallabhaneni S, Putta N, Scott E, Matvey D, Giobbie-Hurder A, Kohler RH, Sarkaria JN, Parangi S, Sorger PK, Agar NYR, Jacene HA, Sullivan RJ, Buchbinder E, Mikula H, Weissleder R, Miller MA. Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv 2022; 8:eabl6339. PubMed
  • Hu H, Quintana J, Weissleder R, Parangi S, Miller M. Deciphering albumin-directed drug delivery by imaging. Adv Drug Deliv Rev 2022; 185:114237. PubMed
  • Cook L, Sengelmann M, Winkler B, Nagl C, Koch S, Schlomann U, Slater EP, Miller MA, von Strandmann EP, Dörsam B, Preußer C, Bartsch JW. ADAM8-Dependent Extracellular Signaling in the Tumor Microenvironment Involves Regulated Release of Lipocalin 2 and MMP-9. Int J Mol Sci 2022. PubMed
  • Matvey DO, Ng TSC, Miller MA. Confocal Imaging of Single-Cell Signaling in Orthotopic Models of Ovarian Cancer. Methods Mol Biol 2022; 2424:295-315. PubMed
  • Luthria G, Lauffenburger D, Miller MA. Cell-Cell Communication Networks in Tissue: Toward Quantitatively Linking Structure with Function. Curr Opin Syst Biol 2021. PubMed
  • Li R, Ng TSC, Wang SJ, Prytyskach M, Rodell CB, Mikula H, Kohler RH, Garlin MA, Lauffenburger DA, Parangi S, Dinulescu DM, Bardeesy N, Weissleder R, Miller MA. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nat Nanotechnol 2021. PubMed
  • Arlauckas S, Oh N, Li R, Weissleder R, Miller MA. Macrophage imaging and subset analysis using single-cell RNA sequencing. Nanotheranostics 2021; 5:36-56. PubMed
  • Stewart-Ornstein J, Iwamoto Y, Miller MA, Prytyskach MA, Ferretti S, Holzer P, Kallen J, Furet P, Jambhekar A, Forrester WC, Weissleder R, Lahav G. p53 dynamics vary between tissues and are linked with radiation sensitivity. Nat Commun 2021; 12:898. PubMed
  • Baskaran JP, Weldy A, Guarin J, Munoz G, Shpilker PH, Kotlik M, Subbiah N, Wishart A, Peng Y, Miller MA, Cowen L, Oudin MJ. Cell shape, and not 2D migration, predicts extracellular matrix-driven 3D cell invasion in breast cancer. APL Bioeng 2020; 4:026105. PubMed
  • Wang SJ, Li R, Ng TSC, Luthria G, Oudin MJ, Prytyskach M, Kohler RH, Weissleder R, Lauffenburger DA, Miller MA. Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. Sci Adv 2020. PubMed
  • Luthria G, Li R, Wang S, Prytyskach M, Kohler RH, Lauffenburger DA, Mitchison TJ, Weissleder R, Miller MA. In vivo microscopy reveals macrophage polarization locally promotes coherent microtubule dynamics in migrating cancer cells. Nat Commun 2020; 11:3521. PubMed
  • Gorry M, Yoneyama T, Vujanovic L, Moss ML, Garlin MA, Miller MA, Herman J, Stabile LP, Vujanovic NL. Development of flow cytometry assays for measuring cell-membrane enzyme activity on individual cells. J Cancer 2020; 11:702-715. PubMed
  • Ng TSC, Garlin MA, Weissleder R, Miller MA. Improving nanotherapy delivery and action through image-guided systems pharmacology. Theranostics 2020; 10:968-997. PubMed
  • Li R, Attari A, Prytyskach M, Garlin MA, Weissleder R, Miller MA. Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics. Cytometry A 2019. PubMed
  • Miller MA, Mikula H, Luthria G, Li R, Kronister S, Prytyskach M, Kohler RH, Mitchison T, Weissleder R. Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation. ACS Nano 2018. PubMed
  • Kim HY, Li R, Ng TSC, Courties G, Rodell CB, Prytyskach M, Kohler RH, Pittet M, Nahrendorf M, Weissleder R, Miller MA. Quantitative Imaging of Tumor Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin. ACS Nano 2018. PubMed
  • Miller MA, Askevold B, Mikula H, Kohler RH, Pirovich D, Weissleder R. Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun 2017; 8:15906. PubMed
  • Miller MA, Weissleder R. Imaging of anticancer drug action in single cells. Nat Rev Cancer 2017; 17:399-414. PubMed
  • Miller MA, Chandra R, Cuccarese MF, Pfirschke C, Engblom C, Stapleton S, Adhikary U, Kohler RH, Mohan JF, Pittet MJ, Weissleder R. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med 2017. PubMed
  • Miller MA, Sullivan RJ, Lauffenburger DA. Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res 2017; 23:623-629. PubMed
  • Yoneyama T, Gorry M, Miller MA, Gaither-Davis A, Lin Y, Moss ML, Griffith LG, Lauffenburger DA, Stabile LP, Herman JG, Vujanovic NL. Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates. J Cancer 2017; 8:3916-3932. PubMed
  • Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, Weissleder R, Flaherty KT, Gertler FB, Lauffenburger DA. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. 2016; 6:382-99. PubMed
Hide